FarrowSure® GOLD B

Dosage

Children: Refer to specific product guidelines or clinical protocols for dosing.

Adults: Refer to specific product guidelines or clinical protocols for dosing.

Pregnancy

The safety of bratislava during pregnancy has not been established. It is advisable to use it only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is unknown whether bratislava is excreted in human milk. Caution should be exercised when administering to breastfeeding women.

Storage

Store at room temperature, away from moisture and heat. Keep out of reach of children.

Indications

• Leptospirosis
• Renal impairment due to leptospirosis
• Hepatic complications associated with leptospirosis

Dosage

Children: Refer to the BNF for Children for appropriate dosing guidance, as no specific dosing is provided.

Adults: Refer to specific guidelines for antibiotic therapy based on the severity and stage of leptospirosis, as no specific dosing is provided.

Mechanism of action

Leptospira canicola, like other leptospires, invades host tissues and elicits an immune response. The bacteria can penetrate mucosal membranes and survive in the renal tubules, leading to inflammation and damage. The immune response involves both humoral and cell-mediated immunity, which can contribute to the clinical manifestations of the disease, including vasculitis and organ dysfunction.

Pharmacodynamics

The pharmacodynamics of treatment for leptospirosis focuses on the elimination of the organism and the resolution of symptoms. Antibiotics, such as doxycycline and penicillin, act by inhibiting bacterial cell wall synthesis or protein synthesis, leading to cell lysis and death. The effectiveness of these treatments is influenced by the timing of administration, as early treatment can prevent severe complications.

Pharmacokinetics

The pharmacokinetics of antibiotics used to treat leptospirosis, such as doxycycline, include rapid absorption from the gastrointestinal tract, high bioavailability, and extensive tissue distribution. Doxycycline, for example, is metabolized by the liver and excreted primarily in the urine. The half-life of doxycycline allows for once or twice daily dosing, making it convenient for treatment regimens.

Pregnancy

Safety during pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether canicola is excreted in human milk. Caution should be exercised when administered to a nursing woman.

Storage

Store in a cool, dry place away from light. Keep out of reach of children.

Indications

• Clinical term 1
• Common term 1
• Clinical term 2
• Common term 2

Dosage

Children: Refer to the BNF for Children for specific paediatric dosing guidelines.

Adults: Refer to the BNF for specific adult dosing guidelines.

Mechanism of action

Dose acts by modulating the activity of specific neurotransmitter receptors and ion channels, influencing various physiological pathways. Its precise mechanism may involve interactions with G-protein coupled receptors, leading to downstream signaling effects that impact cellular responses.

Pharmacodynamics

Dose exhibits a range of effects depending on the dosage and target tissues. It is known to alter neurotransmitter release, affect ion conductance, and influence metabolic pathways, thereby contributing to its therapeutic efficacy and potential side effects.

Pharmacokinetics

Dose is generally absorbed following administration, with peak plasma concentrations occurring within a specified timeframe. Its distribution is influenced by tissue binding and permeability across cell membranes. The drug is metabolized primarily in the liver, with metabolites being excreted via renal and biliary routes. The half-life can vary based on individual patient factors, including age, liver function, and other concurrent medications.

Indications

• Erysipeloid (localized skin infection)
• Systemic infections in immunocompromised patients

Dosage

Children: Refer to specific antibiotic guidelines for treatment based on sensitivity and clinical presentation. Dosing should be carefully calculated based on the child's weight and the specific antibiotic used.

Adults: Refer to specific antibiotic guidelines for treatment based on sensitivity and clinical presentation. Common antibiotics include penicillins or tetracyclines.

Mechanism of action

Erysipelothrix rhusiopathiae adheres to host cells and tissues via surface proteins, which facilitate its invasion. The bacteria produce various virulence factors, including enzymes and toxins that contribute to tissue damage and inflammation. The immune response to Erysipelothrix is primarily mediated by phagocytosis and the activation of the complement system.

Pharmacodynamics

Erysipelothrix rhusiopathiae elicits an inflammatory response characterized by the activation of neutrophils and macrophages. This immune response is crucial for controlling the infection, but it can also lead to tissue damage if the immune response is excessive. Antibiotics effective against the bacteria can help reduce the severity of symptoms and hasten recovery.

Pharmacokinetics

As a bacterium, Erysipelothrix does not follow the pharmacokinetic principles of drugs; however, when treated with antibiotics, the pharmacokinetics would depend on the specific antibiotic used. The distribution, metabolism, and elimination of the antibiotic can significantly influence treatment outcomes.

Adverse effects

• Fever
• Chills
• Malaise
• Skin rash
• Nausea
• Vomiting

Precautions

• Use with caution in patients with a history of hypersensitivity to Erysipelothrix
• Monitor for signs of systemic infection

Pregnancy

Safety during pregnancy has not been established; consult a healthcare professional before use.

Breast-feeding

Consult a healthcare professional before use while breastfeeding as safety has not been established.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Gastroenteritis caused by Salmonella enterica serotype Grippotyphosa
• Systemic infections in immunocompromised patients
• Foodborne illness outbreaks

Dosage

Children: Refer to clinical guidelines for appropriate antibiotic therapy based on susceptibility testing.

Adults: Refer to clinical guidelines for appropriate antibiotic therapy based on susceptibility testing.

Mechanism of action

Grippotyphosa invades the intestinal epithelium, evading the host's immune response. It utilizes a type III secretion system to inject virulence factors into host cells, promoting bacterial entry and survival within macrophages, which leads to systemic infection.

Pharmacodynamics

The pathogenicity of Grippotyphosa is characterized by its ability to induce inflammation and disrupt the intestinal barrier. The bacteria can replicate within macrophages, leading to prolonged immune response and potential dissemination into the bloodstream, causing systemic illness. Antibiotic susceptibility may vary, necessitating sensitivity testing.

Pharmacokinetics

As a bacterial pathogen, Grippotyphosa is not a drug with pharmacokinetic properties. However, when treated with antibiotics, the pharmacokinetics of the chosen antibiotic will dictate its effectiveness against the bacteria. Typically, antibiotics are absorbed, distributed, metabolized, and excreted in a way that targets the infection site effectively.

Pregnancy

Consult a healthcare professional before use. Data on safety in pregnancy is limited.

Breast-feeding

Consult a healthcare professional before use. Limited data on excretion in breast milk.

Storage

Store in a cool, dry place, away from direct sunlight. Keep out of reach of children.

Indications

• Leptospirosis
• Zoonotic infections

Dosage

Children: Refer to the BNF for Children for appropriate dosing in paediatric patients.

Adults: Refer to established treatment guidelines or the BNF for specific antibiotic dosing recommendations for leptospirosis.

Mechanism of action

Leptospira bacteria invade host tissues, evading the immune response and causing tissue damage primarily through the release of lipopolysaccharides (LPS) which can trigger an inflammatory response. The bacteria can also interfere with endothelial cell function, leading to vascular leakage and multi-organ dysfunction.

Pharmacodynamics

The pathogenicity of Leptospira involves adherence to host tissues and the secretion of various virulence factors that modulate host immune responses. The inflammatory response generated can lead to the clinical manifestations of the disease, including fever, myalgia, and in severe cases, jaundice, renal failure, and hemorrhagic symptoms.

Pharmacokinetics

While specific pharmacokinetic data for Hardjo as a bacterial strain is not applicable, the pharmacokinetics of antibiotics used to treat leptospirosis, such as doxycycline or penicillin, include absorption and distribution into body fluids and tissues, metabolism in the liver, and excretion primarily via the kidneys. The timing and route of administration can significantly affect the efficacy of treatment.

Pregnancy

The effects of hardjo during pregnancy have not been well studied; caution is advised.

Breast-feeding

It is not known whether hardjo is excreted in human milk; use with caution.

Storage

Store in a cool, dry place away from direct sunlight.

Indications

• Leptospirosis
• Icterhaemorrhagiae infection
• Severe bacterial infections
• Acute febrile illness

Dosage

Children: Paediatric dosing for leptospirosis requires careful consideration of the child's weight and age, and should be guided by current clinical guidelines and expert recommendations.

Adults: Antibiotic treatment involves specific dosing based on the chosen agent, often guided by renal function and severity of the disease. Refer to specific guidelines for appropriate antibiotic choice and dosing.

Mechanism of action

Leptospirosis is primarily caused by Leptospira bacteria, which invade host tissues and evade the immune response. The bacteria can enter the bloodstream, leading to systemic infection. They produce various virulence factors that impair host immune response, allowing for persistent infection and tissue damage.

Pharmacodynamics

The pharmacodynamics of treatments for leptospirosis, such as antibiotics, involve the inhibition of bacterial cell wall synthesis, protein synthesis, or nucleic acid synthesis, which ultimately leads to bacterial cell death. The effectiveness of treatment is influenced by the stage of the disease and the severity of the infection.

Pharmacokinetics

The pharmacokinetics of antibiotics used to treat leptospirosis vary by drug. Generally, these drugs are absorbed from the gastrointestinal tract, distributed throughout body tissues, and excreted mainly via the kidneys. The half-life and clearance rates depend upon the specific antibiotic used and the patient's renal function.

Pregnancy

The safety of icterohaemorrhagiae during pregnancy has not been established. Caution is advised.

Breast-feeding

It is not known if icterohaemorrhagiae is excreted in human milk. Caution is recommended.

Storage

Store at room temperature, away from light and moisture. Keep out of reach of children.

Indications

• Leptospirosis
• Acute febrile illness
• Renal failure due to leptospirosis
• Severe liver dysfunction
• Hemorrhagic manifestations

Dosage

Adults: Refer to the BNF for appropriate antibiotic treatment regimens based on clinical severity and patient factors

Mechanism of action

Leptospira bacteria invade host tissues and can evade the immune response, leading to systemic infection. They are known to bind to host cells through specific receptors, facilitating their entry and subsequent multiplication. The immune response to the infection may result in an inflammatory response, contributing to tissue damage and the clinical manifestations of leptospirosis.

Pharmacodynamics

The pathophysiology of leptospirosis involves both the virulence factors of Leptospira and the host's immune response. The bacteria can induce a strong inflammatory response, leading to vasculitis and tissue damage. Organ dysfunction may occur due to the direct effects of the bacteria and the resultant immune-mediated injury. The severity of the disease can vary greatly depending on the serovar of Leptospira involved and the host's immune status.

Pharmacokinetics

Leptospira has no direct pharmacokinetics as it is a bacterium rather than a drug. However, the treatment of leptospirosis typically involves antibiotics. Common antibiotics used include doxycycline, penicillin, and ceftriaxone. The pharmacokinetics of these antibiotics vary; for example, doxycycline is well-absorbed orally and has a long half-life, allowing for once or twice daily dosing, while penicillin has a shorter half-life and requires more frequent dosing. The clearance of these drugs is influenced by renal function, which may be compromised in patients with severe leptospirosis.

Adverse effects

• Fever
• Headache
• Muscle pain
• Nausea
• Vomiting
• Jaundice
• Rash
• Meningitis
• Pulmonary hemorrhage
• Acute kidney injury

Precautions

• Monitor renal function in patients with existing kidney issues
• Use caution in immunocompromised patients
• Assess liver function prior to treatment

Pregnancy

The safety of leptospira treatment during pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Not well studied in breastfeeding women. Caution is advised.

Storage

Store at room temperature, away from direct sunlight. Keep out of reach of children.

Indications

• Hypertension
• Angina pectoris
• Migraine prophylaxis
• Tachyarrhythmias
• Heart failure

Dosage

Children: Refer to the BNF for Children for pediatric dosing recommendations, as these will depend on the specific indication and the patient's age and weight.

Adults: Refer to the BNF for specific dosing guidelines, as it may vary based on the condition being treated and individual patient factors.

Mechanism of action

Nadolol exerts its effects by blocking beta-1 and beta-2 adrenergic receptors in the heart and peripheral vasculature. By antagonizing these receptors, nadolol decreases heart rate, myocardial contractility, and conduction velocity through the atrioventricular node, which reduces cardiac workload and oxygen consumption. Additionally, blockade of beta-2 receptors can lead to peripheral vasoconstriction, but this effect is generally outweighed by the overall reduction in heart activity.

Pharmacodynamics

Nadolol reduces heart rate and myocardial oxygen demand by inhibiting the actions of catecholamines on the heart. The drug also has a long half-life, allowing for once-daily dosing. The antihypertensive effects are due to decreased cardiac output and a reduction in renin release from the kidneys, which leads to lower levels of angiotensin II and subsequently vasodilation.

Pharmacokinetics

Nadolol is well absorbed following oral administration, with peak plasma concentrations occurring within 1 to 4 hours. It has a long elimination half-life of approximately 20 to 24 hours, allowing for once-daily dosing. Nadolol is primarily excreted unchanged in the urine, with minimal hepatic metabolism, making it suitable for use in patients with liver dysfunction. The drug's pharmacokinetic profile can be affected by renal impairment, necessitating careful monitoring and potential dose adjustments.

Pregnancy

There are no well-controlled studies of nadl in pregnant women. Its use should be considered only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether nadl is excreted in human milk. Caution should be exercised when administering to a nursing woman.

Storage

Store at room temperature, away from moisture and light. Keep out of reach of children.

Indications

• Fifth disease (erythema infectiosum)
• Aplastic crisis in patients with hemolytic anemia
• Parvovirus B19 infection in immunocompromised patients

Dosage

Children: There are no specific pharmacological treatments for parvovirus infections; management is supportive. In children, parvovirus B19 infection typically resolves on its own, and symptomatic treatment is

Adults: There are no specific pharmacological treatments for parvovirus infections; management is supportive. Adults with parvovirus B19 infection are generally advised to rest and manage symptoms such as fever and pain.

Mechanism of action

Parvovirus B19 infects erythroid progenitor cells in the bone marrow, leading to lysis of these cells and a subsequent decrease in red blood cell production. The virus attaches to its receptor, globoside (also known as P antigen), which is present on the surface of erythroid progenitor cells. This binding facilitates viral entry and replication, disrupting normal erythropoiesis.

Pharmacodynamics

Parvovirus B19's primary effect is on the hematopoietic system, particularly impacting the production of red blood cells. In immunocompetent individuals, infection typically results in mild symptoms and self-limiting disease. However, in individuals with compromised immune systems or underlying hematological conditions, the virus can lead to severe anemia and other complications due to its effect on erythroid progenitors.

Pharmacokinetics

Parvovirus does not follow traditional pharmacokinetic principles as it is a virus rather than a pharmaceutical agent. Its replication occurs intracellularly, and it is spread via respiratory droplets or blood. The incubation period ranges from 4 to 14 days, and viremia can persist for weeks. The immune response is crucial for clearing the virus, with specific antibodies developing within a few weeks of infection.

Adverse effects

• Fever
• Malaise
• Rash
• Joint pain
• Anemia
• Lethargy

Precautions

• Immunocompromised patients may experience more severe symptoms.
• Pregnant women should be cautious due to potential risks to the fetus.

Pregnancy

Parvovirus B19 infection during pregnancy can lead to serious complications, including fetal anemia and hydrops fetalis.

Breast-feeding

There is no evidence to suggest that parvovirus B19 is transmitted through breast milk.

Storage

Parvovirus is a virus and does not require storage in a conventional sense; however, specimens should be handled according to biosafety guidelines.

Dosage

Children: Refer to official prescribing information or clinical guidelines for appropriate paediatric dosing.

Adults: Refer to official prescribing information or clinical guidelines for appropriate adult dosing.

Pregnancy

Data on the use of pomona during pregnancy is limited. It is recommended to assess the risk versus benefit before administration to pregnant patients.

Breast-feeding

The safety of pomona during breastfeeding is not established. Caution is advised, and it is recommended to consult a healthcare provider.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Diabetes mellitus
• Heart valve replacement
• Hormone replacement therapy

Dosage

Children: Refer to specific product guidelines for dosing information, as it varies depending on the formulation and clinical indication.

Adults: Refer to specific product guidelines for dosing information, as it varies depending on the formulation and clinical indication.

Mechanism of action

Porcine insulin, for example, functions by binding to insulin receptors on the surface of cells, facilitating the uptake of glucose into cells, and thus lowering blood glucose levels. This action mimics the physiological response of human insulin, promoting cellular glucose utilization and lipid synthesis.

Pharmacodynamics

The pharmacodynamic effects of porcine-derived products depend on the specific application. For porcine insulin, the primary effect is the reduction of blood glucose levels, leading to improved glycemic control in diabetic patients. The pharmacological effects can vary based on the formulation, such as the rate of absorption and duration of action, which can differ from human insulin.

Pharmacokinetics

The pharmacokinetics of porcine insulin involves absorption, distribution, metabolism, and excretion. After subcutaneous injection, porcine insulin is absorbed into the bloodstream, with peak concentrations typically occurring within 2 to 4 hours. It is metabolized primarily in the liver and kidneys, and its duration of action can vary based on the specific formulation used, such as regular versus long-acting insulins.

Pregnancy

Porcine-derived products should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether porcine-derived products are excreted in human milk. Caution should be exercised when administering to nursing mothers.

Storage

Store at room temperature, away from direct sunlight and moisture. Specific storage conditions may vary based on the formulation.

Indications

• Erysipelas
• Skin infections
• Occupational exposure-related infections

Dosage

Children: Refer to appropriate clinical guidelines or infectious disease protocols for specific dosing information.

Adults: Refer to appropriate clinical guidelines or infectious disease protocols for specific dosing information.

Mechanism of action

Rhusiopathiae produces virulence factors that allow it to adhere to and invade host tissues. These factors may include adhesins that facilitate binding to host cells and toxins that can damage host tissues, leading to inflammation and infection. The bacterium's ability to evade the immune response further contributes to its pathogenicity.

Pharmacodynamics

The pharmacodynamics of rhusiopathiae relates to its interaction with host immune responses and the subsequent inflammatory response it triggers. The bacterium can induce cytokine release, leading to localized inflammation, which is a key feature of the infections it causes. The severity of the infection can vary depending on the host's immune status and the virulence of the bacterial strain.

Pharmacokinetics

Information on the pharmacokinetics of rhusiopathiae is limited due to its nature as a bacterium rather than a conventional drug. However, once introduced into the body, it can disseminate through the bloodstream, potentially leading to systemic infections. The clearance of the organism is primarily through the host's immune system, including phagocytosis by neutrophils and macrophages.

Adverse effects

• Allergic reactions
• Gastrointestinal disturbances
• Nausea
• Vomiting
• Diarrhea

Precautions

• Use with caution in patients with a history of hypersensitivity to rhusiopathiae or related substances
• Monitor patients for allergic reactions
• Consider risks versus benefits in patients with gastrointestinal disorders

Pregnancy

Limited data is available on the safety of rhusiopathiae during pregnancy. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Caution is advised when administering rhusiopathiae to breastfeeding mothers due to limited information on excretion in human milk.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Bacterial infections
• Viral infections
• Epidemiological studies
• Antibiotic resistance monitoring

Dosage

Children: Refer to specific antimicrobial treatment guidelines based on the strain identified and the infection site.

Adults: Refer to specific antimicrobial treatment guidelines based on the strain identified and the infection site.

Mechanism of action

The mechanism of action for a strain depends on the type of microorganism it represents. For pathogenic bacteria, the strain may produce toxins, evade the host's immune response, or possess resistance mechanisms that allow it to survive in the presence of antibiotics. For viruses, strains may exhibit mutations that alter their ability to infect host cells or evade antiviral therapies.

Pharmacodynamics

Pharmacodynamics in the context of strains involves the interaction between the strain and the host's immune system, as well as the effects of specific antimicrobial agents on the strain. These interactions can influence the efficacy of treatments and the development of resistance.

Pharmacokinetics

Pharmacokinetics is not directly applicable to strains themselves but rather to the drugs used to treat infections caused by specific strains. Factors such as absorption, distribution, metabolism, and excretion of antimicrobial agents can vary depending on the strain's characteristics and the site of infection.

Pregnancy

There is limited information on the safety of strain in pregnancy. It is advisable to consult healthcare professionals for guidance.

Breast-feeding

Safety during breastfeeding is not well established. It is recommended to seek medical advice before use.

Storage

Store in a cool, dry place, away from direct sunlight and moisture. Keep out of reach of children.

Dosage

Children: Refer to specific drug guidelines as dosing in units varies based on the drug and its clinical application.

Adults: Refer to specific drug guidelines as dosing in units varies based on the drug and its clinical application.

Mechanism of action

The mechanism of action of drugs measured in units depends on the specific substance. For example, insulin (measured in units) facilitates glucose uptake in cells by binding to insulin receptors, activating a signaling pathway that enhances glucose transporter translocation to the cell membrane. This results in a decrease in blood glucose levels. Similarly, other drugs measured in units may exert their effects through receptor binding, enzyme catalysis, or other biochemical interactions.

Pharmacodynamics

Pharmacodynamics describes the effects of the drug on the body and includes the relationship between drug concentration and effect. For substances measured in units, the pharmacodynamic response may be variable and is often dependent on the individual’s sensitivity to the drug, receptor availability, and other pharmacological factors. For instance, the effect of 1 unit of insulin can vary significantly among individuals based on their insulin sensitivity and metabolic state.

Pharmacokinetics

Pharmacokinetics refers to the absorption, distribution, metabolism, and excretion of drugs. For substances measured in units, the pharmacokinetic profile can differ widely. For instance, insulin is rapidly absorbed when administered subcutaneously, distributed throughout the body, metabolized by the liver and kidneys, and its effects can be observed within minutes. Other drugs may have different absorption rates, half-lives, and routes of elimination.

Pregnancy

Consult a healthcare professional. The safety of this drug during pregnancy has not been established.

Breast-feeding

Consult a healthcare professional. The safety of this drug during breastfeeding has not been established.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.